OTIC

Otonomy, Inc. [OTIC] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

OTIC Stock Summary

In the News

OTIC Financial details

Company Rating
-
Market Cap
582.48K
Income
-52.98M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
0.11
Dividend %
1.29K%
Employees
51
Optionable
No
Shortable
Yes
Earnings
24 Jul 2023
P/E
-0.01
Forward P/E
-
PEG
0
P/S
-
P/B
0.03
P/C
-
P/FCF
-0.02
Quick Ratio
1.59
Current Ratio
1.74
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.79
EPS next Y
-
EPS next Q
-
EPS this Y
-26.17%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-23.06%
Revenue last 5Y
-36.76%
Revenue Q/Q
-
EPS Q/Q
-10%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
23%
ROC
-1.17%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.0075-2.51
52W High
-
52W Low
-
RSI
46
Rel Volume
2.22
Avg Volume
876.96K
Volume
1.94M
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.57173
-
-
Volatility
0.03%, 0.03%
Prev Close
-88.96%
Price
0.0085
Change
-

OTIC Financial Performance

OTIC Dividend History

OTIC Frequently Asked Questions

What is Otonomy, Inc. stock symbol ?

Otonomy, Inc. is a US stock , located in San diego of Ca and trading under the symbol OTIC

What is Otonomy, Inc. stock quote today ?

Otonomy, Inc. stock price is $0.0085 today.

Is Otonomy, Inc. stock public?

Yes, Otonomy, Inc. is a publicly traded company.

Something similar

Top by Market Cap
AAPL
ABEC.DE
AVGO
M&M.NS
EMBASSY.NS
Same Sector
ORTI-A.ST
OKDBV.HE
EPGNY
NRSN
KTTAW
Check Those
FBSOX
DIAMONDYD.NS
KIM-PM
4927.TW
1701.TW
Similar Market Cap
SCOP.L
INR
BRLIR
ITOX
GMBL

Company Profile

Healthcare Biotechnology
  • Volume Average 876.96K
  • Market Capitalization 582.48K
  • Employee 51
  • CEO Mr. David M. Maggio
  • Headquarters San Diego,CA,US
  • IPO Date 2014-08-13
  • Website https://www.otonomy.com

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.